ID   PC3-R-caba
AC   CVCL_WM76
DR   cancercelllines; CVCL_WM76
DR   Wikidata; Q98128508
RX   PubMed=27198502;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_63584; Cabazitaxel.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=27198502; DOI=10.15252/emmm.201506059; PMCID=PMC4931290;
RA   Al Nakouzi N., Wang C.K.-D., Beraldi E., Jager W., Ettinger S.,
RA   Fazli L., Nappi L., Bishop J.L., Zhang F., Chauchereau A., Loriot Y.,
RA   Gleave M.E.;
RT   "Clusterin knockdown sensitizes prostate cancer cells to taxane by
RT   modulating mitosis.";
RL   EMBO Mol. Med. 8:761-778(2016).
//